Literature DB >> 29479229

Adherence to antimuscarinics in children with overactive bladder.

Alexandra Fortin1, Valérie Morin1, Sophie Ramsay2, Pascale Gervais1, Stéphane Bolduc2.   

Abstract

OBJECTIVES: Adherence to antimuscarinics for the treatment of overactive bladder is known to be low in adults but there is scarce data on adherence in paediatric patients. Our objectives were to evaluate the adherence of children to antimuscarinics and to identify influencing factors.
METHODS: Children aged 5 to 18 years and treated with an antimuscarinic agent for at least 6 months were recruited at a routine visit and had to fill out a questionnaire. Their pharmacists were then contacted to inquire about prescription renewals since the beginning of treatment. The medication possession ratio was calculated and grouped by time blocks of 1, 3, 6 and 12 months. The pharmacists were contacted again 6 months after the recruitment visit. A medication possession ratio ≥ 80% was considered as good adherence.
RESULTS: Seventy-two patients were recruited with a mean age of 10.1 years. The self-reported adherence was 93%. Prior to the questionnaire, the medication possession ratio was ≥ 80% in 36%, 57%, 64% and 74% of cases in blocks of 1, 3, 6 and 12 months, respectively. After the questionnaire, the medication possession ratio improved to 53%, 65% and 71% for blocks of 1, 3 and 6 months, respectively. No influencing factors were identified.
CONCLUSIONS: Measured adherence to antimuscarinics in children with overactive bladder is higher than in adults but significantly lower than the self-reported adherence. Good self-reported adherence must be questioned to avoid unnecessary dose escalation or change of medication. Strategies to increase medication adherence are required to improve treatment efficacy.

Entities:  

Keywords:  Anticholinergics; Child; Overactive bladder; Patient adherence.

Year:  2017        PMID: 29479229      PMCID: PMC5804706          DOI: 10.1093/pch/pxx055

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  24 in total

1.  Prospective open label study of solifenacin for overactive bladder in children.

Authors:  Stéphane Bolduc; Katherine Moore; Geneviève Nadeau; Sylvie Lebel; Pascale Lamontagne; Micheline Hamel
Journal:  J Urol       Date:  2010-08-21       Impact factor: 7.450

2.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

3.  Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the california medicaid program.

Authors:  Yanni F Yu; Michael B Nichol; Andrew P Yu; Jeonghoon Ahn
Journal:  Value Health       Date:  2005 Jul-Aug       Impact factor: 5.725

4.  Medication adherence in persons with cardiovascular disease.

Authors:  Jacqueline Dunbar-Jacob; Patricia Bohachick; Mary Kay Mortimer; Susan M Sereika; Susan M Foley
Journal:  J Cardiovasc Nurs       Date:  2003 Jul-Aug       Impact factor: 2.083

Review 5.  Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review.

Authors:  Simona Bartoli; Giovanni Aguzzi; Rosanna Tarricone
Journal:  Urology       Date:  2009-12-04       Impact factor: 2.649

6.  Challenges for managing overactive bladder and guidance for patient support.

Authors:  Vernon F Schabert; Tamara Bavendam; Erica L Goldberg; Jeffrey N Trocio; Linda Brubaker
Journal:  Am J Manag Care       Date:  2009-03       Impact factor: 2.229

7.  Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro-Artieda; Alba Aguado-Jodar; Amador Ruiz-Torrejón; Jordi Ibáñez-Nolla; Marion Kvasz
Journal:  Int Urogynecol J       Date:  2013-11-06       Impact factor: 2.894

8.  Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.

Authors:  H H Sung; D H Han; T H Kim; Y-S Lee; H N Lee; J T Seo; M-S Choo; K-S Lee
Journal:  Int J Clin Pract       Date:  2015-07-28       Impact factor: 2.503

9.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

10.  Patient-reported reasons for discontinuing overactive bladder medication.

Authors:  Joshua S Benner; Michael B Nichol; Eric S Rovner; Zhanna Jumadilova; Jose Alvir; Mohamed Hussein; Kristina Fanning; Jeffrey N Trocio; Linda Brubaker
Journal:  BJU Int       Date:  2009-11-12       Impact factor: 5.588

View more
  1 in total

1.  First North American experience of propiverine use in children with overactive bladder.

Authors:  Élisabeth Lapointe; Narcisse Singbo; Élizabeth Naud; Stéphane Bolduc
Journal:  Can Urol Assoc J       Date:  2022-10       Impact factor: 2.052

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.